



02-11-08

Attorney's Docket No.: 17109-002001 / 911

1631

ff

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Manuel Vega et al.

Serial No. : 10/022,249

Filed : December 17, 2001

Cust. No. : 20985

Title : HIGH THROUGHPUT DIRECTED EVOLUTION BY RATIONAL  
MUTAGENESIS

Art Unit : 1631

Examiner : Jerry Lin

Conf. No. : 7196

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**


Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement (5 pages); Form PTO-1449 (1 page); cited non U.S. patent documents; copy of a European Examination Report, issued July 31, 2007, in connection with European Patent Application No. 02798018.4; copies of three U.S. Office actions, issued May 9, 2006, March 12, 2007, and December 10, 2007, in connection U.S. Application Ser. No. 10/658,355; copies of two European Examination Reports, issued August 2, 2005 and June 2, 2006, in connection with European Patent Application No. 03748392.2; return postcard; and a check for the requisite fee of \$180.00 for filing in connection with the above-captioned patent application.



The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

  
Stephanie Seidman

Reg. No. 33,779

Attorney Docket No. 17109-002001 / 911

Address all correspondence to:

Stephanie Seidman

Fish & Richardson P.C.

12390 El Camino Real

San Diego, California 92130

Telephone: (858) 678-4777

Facsimile: (202) 626-7796

email: seidman@fr.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EV 965985825 US

Date of Deposit February 7, 2008

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR § 1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

  
Stephanie Seidman



Attorney's Docket No.: 17109-002001 / 911

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Manuel Vega et al. Art Unit : 1631  
Serial No. : 10/022,249 Examiner : Jerry Lin  
Filed : December 17, 2001 Conf. No. : 7196  
Cust. No. : 20985  
Title : HIGH THROUGHPUT DIRECTED EVOLUTION BY RATIONAL  
MUTAGENESIS

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN**  
**ACCORDANCE WITH 37 C.F.R. §§1.97-1.98**

Dear Sir:

Because this Supplemental Information Disclosure Statement is after receipt of a first Office Action on the Merits of the above-captioned application, the filing fee of \$180 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and copies of the cited non U.S. patent documents are provided herewith in connection with the above-captioned application.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EV 965985825 US

Date of Deposit February 7, 2008

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman

02/12/2008 CCHAU1 00000070 10022249

01 FC:1806

180.00 OP

The documents listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed item is necessary.

A copy of a European Examination Report (Document I), issued July 31, 2007, in connection with corresponding European Patent Application No. 02798018.4 is provided. Copies of three U.S. Office Actions (Documents II, III and IV), issued May 9, 2006, March 12, 2007, and December 10, 2007, respectively, in connection with co-owned U.S. Application Ser. No. 10/658,355 are provided. Copies of two European Examination Reports (Documents V and VI), issued August 2, 2005 and June 2, 2006, respectively, in connection with European Patent Application No. 03748392.2 are provided. European Patent Application No. 03748392.2 corresponds to U.S. Application Ser. No. 10/658,355. The table below lists Documents I-VI and includes a column that provides a space next to the documents to be considered, for the Examiner's initials.

Examiner Initial	Document No.	Document
	I	Copy of European Examination Report, issued July 31, 2007, in connection with European Patent Application No. 02798018.4
	II	Copy of U.S. Office Action, issued May 9, 2006, in connection with U.S. Application Ser. No. 10/658,355
	III	Copy of U.S. Office Action, issued March 12, 2007, in connection with U.S. Application Ser. No. 10/658,355
	IV	Copy of U.S. Office Action, issued December 10, 2007, in connection with U.S. Application Ser. No. 10/658,355
	V	Copy of European Examination Report, issued August 2, 2005, in connection with European Patent Application No. 03748392.2
	VI	Copy of European Examination Report, issued June 2, 2006, in connection with European Patent Application No. 03748392.2

In the U.S. Office Action, issued May 9, 2006 (Document II), three documents are cited: 1) US 5,096,815, 2) Alam et al., "Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro," *J. Biochem.* 65:183-190 (1998), and 3) Chiang et al., "In vivo genetic analysis of bacterial virulence," *Ann. Rev. Microbiology* 53:129-154 (1999). Documents 1-3 are made of record in

the instant application in an Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents, filed June 22, 2006. In the U.S. Office Action, issued March 12, 2007 (Document III), one document is cited: 1) Stabach et al., "Site-directed mutagenesis of alpha II spectrin at codon 1175 modulates its mu-calpain susceptibility," *Biochemistry* 36:57-65 (1997). Document 1 is made of record in the instant application in this Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents. In the U.S. Office Action, issued December 10, 2007 (Document IV), four documents are cited: 1) US 6,548,640, 2) Jones et al., "The rapid generation of mutation data matrices from protein sequences" *CABIOS* 8:275-282 (1992), 3) Alam et al., "Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro," *J. Biochem.* 65:183-190 (1998), and 4) Chiang et al., "In vivo genetic analysis of bacterial virulence," *Ann. Rev. Microbiology* 53:129-154 (1999). Documents 1-2 are made of record in the instant application in this Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents. Documents 3-4 are made of record in the instant application in an Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents, filed June 22, 2006.

In the European Examination Report, issued August 2, 2005 (Document V), five documents are cited: 1) US 5,223,409, 2) WO 01/61344, 3) Manetti et al., "Design and realization of a tailor-made enzyme to modify the molecular recognition of 2-arylpropionic esters by *Candida rugosa* lipase," *Biochem. Biophys. Acta.* 1543(1):146-158 (2000), 4) WO 03/023032 5) Lewerenz et al., "Shared receptor components but distinct complexes for alpha and beta interferons," *J. Mol. Biol.* 282(3):585-599 (1998). Documents 1-5 are made of record in the instant application in an Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents, filed March 15, 2005. In the European Examination Report, issued June 2, 2006 (Document VI), three documents are cited: 1) US 6,013,478, 2) WO 95/23813, 3) WO 01/32844. Documents 1-3 are made of record in the instant application in an Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents, filed March 15, 2005.

Applicant : Manuel Vega et al.  
Serial No. : 10/022,249  
Filed : December 17, 2001

Attorney's Docket No.: 17109-002001 / 911  
Supplemental Information Disclosure Statement

Further to the list provided in the communication filed on March 2, 2007, applicant also makes known to the examiner the following pending U.S. and International Applications that have one or more common inventors and/ or are commonly owned:

<b>U.S.S.N.</b>	<b>Filing Date</b>	<b>Publication or Issue No.</b>	<b>Publication or Issue Date</b>	<b>Docket No.</b>
11/267,871	11/03/05	2007-0249532	10/25/07	925
11/656,921	01/22/07	2007-0254838	11/01/07	922E
11/703,610	02/06/07	n/a	n/a	922C
11/704,141	02/07/07	n/a	n/a	922D
11/706,088	02/13/07	2007-0172459	07/26/07	922F
11/707,014	02/14/07	2007-0224665	09/27/07	922G
11/729,267	03/27/07	n/a	n/a	924
11/729,266	03/27/07	n/a	n/a	924B
11/788,836	04/19/07	n/a	n/a	932
11/818,985	06/15/07	n/a	n/a	930
11/825,604	07/05/07	n/a	n/a	922H
<b>Int'l App. No.</b>	<b>Filing Date</b>	<b>Publication No.</b>	<b>Publication Date</b>	<b>Docket No.</b>
PCT/IB06/002034	05/04/06	WO 06/120580	11/16/06	926PC
PCT/EP07/002700	03/27/07	WO 07/110231	10/04/07	924PC
PCT/US07/14219	06/15/07	n/a	n/a	930PC


Although these documents and applications are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97 (g and h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56 (b) exists.

Applicant respectfully requests that the Examiner review the foregoing documents and make them of record in the file history of the above-captioned application.

Applicant : Manuel Vega et al.  
Serial No. : 10/022,249  
Filed : December 17, 2001

Attorney's Docket No.: 17109-002001 / 911  
Supplemental Information Disclosure Statement

Respectfully submitted,

  
Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 17109-002001 / 911

**Address all correspondence to:**

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-4777  
Facsimile: (202) 626-7796  
email: seidman@fr.com